Title: Elevar Therapeutics' FDA Update on Liver Cancer Drug Combination Approval
Elevar Therapeutics recently announced that the U.S. FDA did not approve its drug combination for a specific type of liver cancer due to deficiencies found during a manufacturing site inspection. The company, which is mostly owned by Korea's HLB Co, had sought approval for rivoceranib and camrelizumab as a first-line treatment for unresectable or metastatic hepatocellular carcinoma, a form of liver cancer that cannot be fully removed by surgery due to its size or location, or because it has spread to distant organs or tissues. CEO Dong-Gun Kim stated that Elevar is reviewing the FDA's feedback and plans to collaborate closely with the agency to determine the next steps.
Kim emphasized the company's commitment to understanding the FDA's feedback and finding the most effective path forward. Elevar intends to engage promptly with the FDA to address the identified deficiencies and work towards gaining approval for its drug combination. The company is focused on ensuring that the necessary steps are taken to meet the regulatory requirements for the treatment of hepatocellular carcinoma.
Elevar Therapeutics is dedicated to advancing treatments for liver cancer and remains determined to navigate the regulatory process to bring its drug combination to patients in need. The company's collaboration with the FDA underscores its commitment to addressing the deficiencies and pursuing the necessary steps to secure approval for rivoceranib and camrelizumab as a potential first-line therapy for unresectable or metastatic hepatocellular carcinoma.